PharmiNews

The Directory of Pharma Companies and News

Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 30 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co. Inc., Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium.
Category: Biotech
Category: Biotech

Ablynx News

DateNews
2017-01-05ABLYNX TO PRESENT AT THE 35th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE (PDF)
2016-09-15ABLYNX RECEIVES TRANSPARENCY NOTIFICATION FROM OPPENHEIMER FUNDS, INC. (PDF)
2016-09-06ABLYNX RECEIVES TRANSPARENCY NOTIFICATION FROM GAM HOLDING AG, GAM INTERNATIONAL MANAGEMENT LIMITED AND TAUBE HODSON STO... (PDF)
2016-08-25ABLYNX ANNOUNCES 2016 HALF-YEAR RESULTS AND YEAR-TO-DATE BUSINESS UPDATE (PDF)
2016-08-17ABLYNX WILL ANNOUNCE ITS 2016 HALF YEAR RESULTS WITH WEBCAST ON 25 AUGUST 2016 (PDF)
2016-08-12ABLYNX RECEIVES TRANSPARENCY NOTIFICATION FROM ADRIANUS VAN HERK ANDVAN HERK INVESTMENTS B.V. (PDF)
2016-08-09ABLYNX REPORTS COMPELLING TOPLINE PHASE IIb STUDY RESULTS WITH ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB, IN RA PATIENTS, C... (PDF)
2016-08-04BANK OF AMERICA CORPORATION ANNOUNCE 5.24% SHAREHOLDING IN ABLYNX (PDF)
2016-07-07ABLYNX ANNOUNCES POSITIVE TOPLINE RESULTS FROM A PHASE IIb STUDY OF ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB (ALX-0061), A... (PDF)
2016-06-16VAN HERK INVESTMENTS ANNOUNCE 3.02% SHAREHOLDING IN ABLYNX (PDF)
2016-06-16CORRECTION TRANSPARENCY NOTIFICATION - ADRIANUS VAN HERK ANNOUNCES 3.02% SHAREHOLDING IN ABLYNX (PDF)
2016-06-10PUBLICATION IN ACCORDANCE WITH ARTICLE 15 OF THE BELGIAN LAW OF 2 MAY 2007 ON THE PUBLICATION OF MAJOR SHAREHOLDINGS (TH... (PDF)
2016-06-03ABLYNX TO PRESENT AT THE ANNUAL JEFFERIES HEALTHCARE CONFERENCE 2016 (PDF)
2016-05-26ABLYNX TO PRESENT A POST-HOC ANALYSIS OF THE PHASE II TITAN STUDY WITH CAPLACIZUMAB IN ACQUIRED TTP PATIENTS AT THE 21st... (PDF)
2016-05-12ABLYNX REPORTS FINANCIAL RESULTS FOR THE FIRST THREE MONTHS OF 2016 AND PROVIDES BUSINESS UPDATE YEAR-TO-DATE (PDF)
2016-05-03ABLYNX REPORTS POSITIVE TOP LINE RESULTS FOR ITS INHALED ANTI-RSV NANOBODY (ALX-0171) IN A PHASE I/IIa STUDY IN INFANTS ... (PDF)
2016-04-29ABLYNX ANNOUNCES MILESTONE IN DRUG DISCOVERY COLLABORATION (PDF)
2016-04-21ABLYNX TO RECEIVE AN €8 MILLION MILESTONE AS BOEHRINGER INGELHEIM STARTS A PHASE I STUDY WITH AN ANTI-CX3CR1 NANOBODY (PDF)
2016-02-25ABLYNX ANNOUNCES 2015 FULL YEAR RESULTS (PDF)
2016-02-18ABLYNX WILL ANNOUNCE ITS 2015 FULL YEAR RESULTS WITH WEBCAST ON 25 FEBRUARY 2016 (PDF)
2016-02-11NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES ABLYNX'S PHASE II TITAN STUDY OF CAPLACIZUMAB IN PATIENTS WITH ACQUIRED TTP (PDF)
2016-01-29ABLYNX TO RECEIVE €8 MILLION MILESTONE AS BOEHRINGER INGELHEIM STARTS FIRST PATIENT STUDY WITH A BI-SPECIFIC NANOBODY IN... (PDF)
2016-01-18PERCEPTIVE ADVISORS LLC ANNOUNCE 5.06% SHAREHOLDING IN ABLYNX (PDF)
2016-01-07ABLYNX TO PRESENT AT THE 34th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE (PDF)
2015-12-17ABLYNX COMPLETES ENROLMENT OF THE FIRST-IN-INFANT PHASE I/IIa SAFETY STUDY WITH ITS ANTI-RSV NANOBODY AND EXTENDS THE TR... (PDF)
2015-12-02JP MORGAN ASSET MANAGEMENT HOLDINGS ANNOUNCE 3.33% SHAREHOLDING IN ABLYNX (PDF)
2015-11-30ABLYNX APPOINTS ROBERT K. ZELDIN, MD, CHIEF MEDICAL OFFICER (PDF)
2015-11-25ABLYNX ANNOUNCES NANOBODY DRUG DISCOVERY COLLABORATION WITH NOVO NORDISK (PDF)
2015-11-18ABLYNX PROVIDES BUSINESS UPDATE FOR THE FIRST NINE MONTHS OF 2015 (PDF)
2015-11-05ABLYNX'S PARTNER BOEHRINGER INGELHEIM PRESENTED POSITIVE IN VIVO PROOF-OF-MECHANISM DATA WITH BI-SPECIFIC NANOBODY AT EU... (PDF)
2015-10-15ABLYNX ACHIEVES FIRST MILESTONE IN IMMUNO-ONCOLOGY COLLABORATION WITH MERCK & CO., INC. (PDF)
2015-09-29ABLYNX INITIATES A MULTINATIONAL PHASE III STUDY WITH CAPLACIZUMAB IN PATIENTS WITH ACQUIRED TTP, A RARE BLOOD CLOTTING ... (PDF)
2015-08-27ABLYNX ANNOUNCES HALF-YEAR RESULTS FOR 2015 (PDF)
2015-08-19ABLYNX TO HOST WEBCAST FOR ITS 2015 HALF-YEAR RESULTS ON 27 AUGUST (PDF)
2015-08-04ABLYNX INITIATES PHASE II SLE STUDY WITH ITS ANTI-IL-6R NANOBODY, PARTNERED WITH ABBVIE (PDF)
2015-07-29PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDI... (PDF)
2015-07-22ABLYNX SIGNIFICANTLY EXPANDS ITS IMMUNO-ONCOLOGY COLLABORATION WITH MERCK & CO., INC. (PDF)
2015-07-14OPPENHEIMER FUNDS, INC. ANNOUNCE 3.07% SHAREHOLDING IN ABLYNX (PDF)
2015-07-01TAUBE HODSON STONEX PARTNERS LLP ANNOUNCE 5.14% SHAREHOLDING IN ABLYNX (PDF)
2015-06-30ABLYNX AND TAISHO SIGN EXCLUSIVE LICENSE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALISATION OF ANTI-TNFa NANOBODY (OZOR... (PDF)
2015-06-17ABLYNX ANNOUNCES PRESENTATIONS ON ITS POTENTIAL FIRST-IN-CLASS TREATMENT FOR ACQUIRED TTP, CAPLACIZUMAB, AT THE 2015 ANN... (PDF)
2015-05-28ABLYNX TO PRESENT AT THE ANNUAL JEFFERIES 2015 GLOBAL HEALTHCARE CONFERENCE (PDF)
2015-05-26FMR LLC ANNOUNCE 5.07% SHAREHOLDING IN ABLYNX (PDF)
2015-05-22TAUBE HODSON STONEX PARTNERS LLP ANNOUNCE 4.35% SHAREHOLDING IN ABLYNX (PDF)
2015-05-20ABLYNX ANNOUNCES FINAL TERMS OF THE EUR 100 MILLION SENIOR UNSECURED CONVERTIBLE BONDS DUE MAY 2020 (PDF)
2015-05-20ABLYNX ANNOUNCES SUCCESSFUL PLACEMENT OF EUR 100 MILLION SENIOR UNSECURED CONVERTIBLE BONDS DUE MAY 2020 (PDF)
2015-05-20ABLYNX LAUNCHES A PRIVATE PLACEMENT OF UP TO EUR 100 MILLION IN SENIOR UNSECURED CONVERTIBLE BONDS DUE MAY 2020 (PDF)
2015-05-18GENZYME TO COLLABORATE WITH ABLYNX ON MULTIPLE SCLEROSIS RESEARCH PROJECT (PDF)
2015-05-13ABLYNX ANNOUNCES BUSINESS UPDATE AND FINANCIAL RESULTS FOR THE FIRST THREE MONTHS OF 2015 (PDF)
2015-05-07ABLYNX PRESENTS UNIQUE NANOBODY DRUG INHALATION TECHNOLOGY AT THE RESPIRATORY DRUG DELIVERY EUROPE 2015 CONFERENCE (PDF)
2015-04-15FMR LLC PROVIDE NOTIFICATION OF SHAREHOLDING IN ABLYNX (PDF)
2015-04-07ABLYNX ANNOUNCES PUBLICATION OF 2014 ANNUAL REPORT AND LAUNCH OF NEW WEBSITE (PDF)
2015-04-07ABLYNX INITIATES THE SECOND OF TWO PHASE IIb RA STUDIES WITH ITS ANTI-IL-6R NANOBODY, PARTNERED WITH ABBVIE (PDF)
2015-03-26ABLYNX ANNOUNCES EXTENSION OF ION CHANNEL RESEARCH COLLABORATION WITH MERCK & CO., INC. (PDF)
2015-03-17ABLYNX INITIATES THE FIRST OF TWO PHASE IIb RA STUDIES WITH ITS ANTI-IL-6R NANOBODY, PARTNERED WITH ABBVIE (PDF)
2015-03-16ABLYNX ANNOUNCES WARRANT EXERCISE (PDF)
2015-03-16POLAR CAPITAL FUNDS PLC AND FMR LLC PROVIDE NOTIFICATION OF SHAREHOLDING IN ABLYNX (PDF)
2015-03-03AVIVA PLC AND AVIVA INVESTORS GLOBAL SERVICES LIMITED PROVIDE NOTIFICATION OF A 5.02% SHAREHOLDING IN ABLYNX (PDF)
2015-02-26ABLYNX ANNOUNCES 2014 FULL YEAR RESULTS (PDF)
2015-02-19ABLYNX WILL ANNOUNCE ITS FULL YEAR RESULTS 2014 WITH WEBCAST (PDF)
2015-01-22ABLYNX SUCCESSFULLY OPPOSES PATENT APPEAL CASE BY DOMANTIS (GSK) (PDF)
2015-01-07ABLYNX TO PRESENT AT THE 33rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE (PDF)
Brought to you by PharmiWeb.com - Latest Jobs in Pharma
Brought to you by www.pharmiweb.com - Latest Jobs in Pharma.